Illustrative pack image. Actual packaging may differ.
VARPOD CV Tablet
Enhanced Broad-Spectrum Antibiotic for Resistant Bacterial Infections
Composition
Cefpodoxime 200 mg + Potassium Clavulanate 125 mg
- Prescription medicine
- Available to order
Overview
VARPOD CV combines Cefpodoxime, a third-generation cephalosporin antibiotic, with Potassium Clavulanate, a potent β-lactamase inhibitor. This synergistic combination enhances the effectiveness of Cefpodoxime, allowing it to overcome bacterial resistance caused by β-lactamase-producing organisms, thus offering a more comprehensive solution for various bacterial infections.
Key Benefits
- Broad-Spectrum Efficacy: Targets a wide range of both gram-positive and gram-negative bacteria
- Overcomes Antibiotic Resistance: Potassium Clavulanate protects Cefpodoxime from β-lactamase degradation, ensuring optimal performance
- Effective Against Resistant Strains: Useful in treating infections caused by resistant pathogens
- Well-Tolerated: Proven to be well-accepted by patients with minimal side effects
- Convenient Dosage: Simple once or twice-daily dosing for patient compliance
Indications
- Respiratory Tract Infections (e.g., pneumonia, bronchitis)
- Urinary Tract Infections (e.g., cystitis, pyelonephritis)
- Skin and Soft Tissue Infections
- Ear Infections (e.g., otitis media)
- Sinusitis
- Gonorrhea and other sexually transmitted infections
